SARS-CoV-2T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. Tondel C, Jenum S, Tonby K, Christensen EE, et al. Vaccine 2026;75:128290.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tondel C, Jenum S, Tonby K, Christensen EE, et al. SARS-CoV-2T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. Vaccine 2026;75:128290.
PMID: 41628524